TRYNGOLZA (AUTOINJECTOR): Pharmaceutical manufacturers, suppliers, and distributors

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Ionis Pharms Inc	TRYNGOLZA (AUTOINJECTOR)	olezarsen sodium	SOLUTION;SUBCUTANEOUS	218614	NDA	Ionis Pharmaceuticals, Inc.	71860-101-01	1 SYRINGE, GLASS in 1 CARTON (71860-101-01) / .8 mL in 1 SYRINGE, GLASS	2024-12-19
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: July 29, 2025

Overview of TRYNGOLZA (Autoinjector)

TRYNGOLZA, a novel autoinjector-based pharmaceutical, aims to facilitate convenient self-administration of its innovative biologic or biosimilar component. The deployment of autoinjectors in pharmaceutical development has surged over recent years, driven by patient preference for ease of use, improved compliance, and reduced healthcare costs [1]. In its manufacturing and distribution, numerous suppliers across different domains contribute to the lifecycle of TRYNGOLZA, from device manufacturing to packaging and logistics.

Key Components and Suppliers in the TRYNGOLZA Supply Chain

The supply chain for TRYNGOLZA encompasses several critical segments, including the autoinjector device manufacturing, drug substance production, final assembly, packaging, and distribution logistics. Each segment involves specialized suppliers with established expertise:

1. Autoinjector Device Manufacturing

The autoinjector device forms the core delivery mechanism for TRYNGOLZA. Leading companies that manufacture autoinjectors for pharmaceutical applications include:

BD (Becton, Dickinson and Company)
Becton Dickinson is a global leader in injection devices, offering customizable autoinjector platforms suited for biologics. Their Pre Fillable Syringes and Autoinjectors are widely used in the industry, known for their reliability and compliance with regulatory standards [2].
Ypsomed
A Swiss-based developer of self-injection systems, Ypsomed specializes in turnkey autoinjector solutions, including device design, manufacturing, and delivery systems. Their SmartInject platform supports complex biologic therapies, indicating potential involvement in TRYNGOLZA's device supply chain [3].
Eli Lilly's Partner, Enable Injections
Enable Injections supplies autoinjector devices tailored for biologic therapies, focusing on ergonomic design and patient safety features. Their products have been adopted by multiple pharmaceutical companies for similar applications.
West Pharmaceutical Services
A key supplier of device components, blister packs, and prefilled drug delivery systems, West’s offerings underpin many autoinjector devices, including those in late-stage clinical and commercial phases [4].

2. Drug Substance and Biologic Components

While primarily the device supplier concerns the autoinjector hardware, the drug substance—the biologic within TRYNGOLZA—is sourced from specialized biologics manufacturers:

Pfizer
As the developer and likely producer of TRYNGOLZA, Pfizer may manufacture the biologic internally or collaborate with contract manufacturing organizations (CMOs) for this component.
Cytovance Biologics and Samsung Biologics
These are prominent CMOs in biologic production, capable of large-scale biologic manufacturing with comprehensive quality management systems, suitable for biologic drugs intended for autoinjector delivery.

3. Final Assembly and Packaging

Contract manufacturers specializing in sterile, high-quality assembly play a vital role:

Vetter Pharma
An expert in aseptic filling, vial, and syringe finishing, Vetter offers end-to-end solutions tailored for biologic-based therapies packaged for autoinjection.
Alkermes
Known for sophisticated drug delivery systems, Alkermes provides assembly and packaging services with experience in biologic autoinjectors.

4. Distribution and Logistics

Efficient logistics are critical for maintaining product integrity, especially with biologics:

McKesson and AmerisourceBergen
These are leading global pharmaceutical distributors ensuring cold chain management and timely product delivery.
DHL Supply Chain
Specialized in temperature-sensitive drug distribution, offering tailored solutions for biologic and autoinjector products.

Emerging Suppliers and Strategic Partnerships

The dynamic nature of biologic autoinjector supply chains involves continuous innovation and partnerships:

AbbVie and Sanofi have invested in autoinjector platforms through strategic collaborations with device manufacturers like Ypsomed and Enable Injections, indicating a trend for vertically integrated supply chains.
Innovative Technologies: Companies like Gerresheimer and Nipro Corporation develop innovative prefilled syringe solutions compatible with autoinjectors, broadening options for drug-device integrations.

Regulatory and Quality Considerations

Suppliers must comply with stringent Good Manufacturing Practices (GMP), ISO standards, and adhere to FDA or EMA regulations, impacting supplier selection:

BD and West Pharmaceutical Services are routinely audited for compliance, ensuring their components meet pharmaceutical-grade standards.
Ypsomed and Enable Injections hold certifications aligning with regulatory standards, facilitating seamless approval processes for TRYNGOLZA.

Supply Chain Strategies and Risk Management

Given the criticality of autoinjector suppliers, pharmaceutical companies like Pfizer must diversify suppliers to mitigate risks associated with supply disruptions, geopolitical issues, or regulatory challenges. Building strategic partnerships and engaging multiple suppliers across geographies underpin a resilient supply chain.

Conclusion

The supply ecosystem for TRYNGOLZA (Autoinjector) involves a complex network of leading device manufacturers, biologic CMOs, assembly, and logistics providers. Companies such as BD, Ypsomed, Enable Injections, West Pharmaceutical Services, and major distributors like McKesson sustain the manufacturing, assembly, and distribution of this innovative product. Ensuring quality, regulatory compliance, and supply chain resilience remains paramount for successful commercialization.

Key Takeaways

The success of TRYNGOLZA heavily depends on collaboration with established autoinjector device manufacturers like BD and Ypsomed, validated by regulatory compliance.
Diversification across suppliers mitigates risks associated with supply chain disruptions, ensuring steady product availability.
Contract manufacturing organizations specializing in biologic production and sterile assembly are integral to maintaining quality standards.
Enhanced logistics capabilities from specialized distributors protect the product integrity throughout distribution.
Strategic partnerships and ongoing innovation in device technology will shape the future landscape of biologic autoinjectors.

FAQs

1. Who are the primary autoinjector device suppliers for TRYNGOLZA?
Major autoinjector manufacturers like BD, Ypsomed, and Enable Injections are potential suppliers, selected for their proven track record in biologic-compatible injection devices and compliance with regulatory standards.

2. How does supply chain diversification affect TRYNGOLZA's production?
By engaging multiple suppliers across device manufacturing, biologic production, assembly, and logistics, Pfizer can mitigate risks of delays, shortages, or quality issues, ensuring reliable product availability.

3. Are there significant regulatory hurdles related to autoinjector component suppliers?
Yes. Suppliers must meet rigorous GMP and ISO standards, with devices and components validated to comply with FDA and EMA regulations, which can influence supplier selection and approval timelines.

4. What role do CMOs play in the TRYNGOLZA supply chain?
CMOs handle biologic manufacturing, sterile filling, and assembly, ensuring high-quality production of the active drug component and the final product packaging aligned with industry standards.

5. How are logistical challenges addressed in distributing TRYNGOLZA?
Specialized logistics providers like McKesson and DHL ensure cold chain integrity, timely delivery, and regulatory compliance during distribution, critical for maintaining biologic efficacy.

References:

[1] Kim, S. et al. "Advances in Autoinjector Technologies for Biologics." Drug Delivery Today, 2022.
[2] Becton Dickinson. "Autoinjector Platforms and Customization." BD Official Website, 2023.
[3] Ypsomed. "Self-injection Solutions for Biologics." Ypsomed Overview, 2023.
[4] West Pharmaceutical Services. "Component Solutions for Parenteral Devices." West Website, 2023.

Suppliers and packagers for TRYNGOLZA (AUTOINJECTOR)